Phase 1/2 trial of 177Lu-DOTA-EB-TATE, somatostatin receptor directed beta emitter

This open-label study tests a three-dose regimen of 177Lu-DOTA-EB-TATE to assess safety, dosimetry, and efficacy in adults with metastatic, radioactive iodine non-responsive Hurthle cell thyroid cancer. Sponsored by NIDDK in Bethesda, the trial evaluates a targeted radiopharmaceutical approach for a rare cancer with limited treatment options.